BIO 300 and radiation for lung cancer with lung scarring
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have early-stage (stage I or II) non-small cell lung cancer.
- You have interstitial lung disease (lung scarring) diagnosed by a pulmonologist, by imaging, or due to a connective tissue disease.
- You are able to care for yourself (ECOG performance status 0-3).
- You have not had radiation to the chest before.
- You have not had a lung removed (pneumonectomy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of radiation therapy, an immunotherapy drug called tislelizumab, and chemotherapy for people with bulky stage III non-small cell lung cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with stereotactic body radiation therapy (SBRT) for people with early-stage non-small cell lung cancer. The goal is to see if this treatment can help shrink or control the cancer before surgery.
This trial tests whether delivering radiation to a smaller target area is as effective for certain inoperable stage III lung cancers, while potentially reducing side effects. It mainly looks for people who can safely receive a standard course of treatment and whose blood tests and health status fit the study rules.
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a treatment for people with advanced non-small cell lung cancer who also have interstitial lung disease (a type of lung scarring). It aims to find out if the treatment is safe and effective for this specific group of patients.
Hear when a new NSCLC, Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.